Answers are grounded in this paper and cite their sources.
Inhibition of collagen biosynthesis in fibroblasts by captopril suggests its role in dermatological side effects.
The mechanism underlying the dermatological manifestations that accompany captopril therapy is not known. The facts that prolidase plays an important role in collagen biosynthesis and that captopril directly inhibits prolidase activity led us to evaluate its effect on collagen biosynthesis in cultured human skin fibroblasts. Confluent fibroblasts were treated with milimolar concentrations (0.2–1 mM) of captopril (CAP) for 48 h. It was found that CAP-dependent decrease in prolidase activity was accompanied by parallel decrease in collagen biosynthesis. Since insulin-like growth factor receptor (IGF-IR) is the most potent regulator of both collagen biosynthesis and prolidase activity, and prolidase is regulated by 1 integrin signaling, the effect of CAP on IGF-IR and 1 integrin receptor expressions was evaluated. It was found that exposure of the cells to 0.3 mM CAP contributed to a decrease in IGF-IR, α21 integrin receptor and MAPK/ ERK1/2 expressions. The data suggest that CAP-dependent decrease of collagen biosynthesis in cultured human skin fibroblasts results from inhibition of prolidase activity that may occur through inhibition of α21 integrin and IGF-IR signaling.
No takes yet. Share an insight, caveat, or question.
Karna et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: